article thumbnail

Bioavailability Enhancement Technologies

Roots Analysis

Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by industry stakeholders.

article thumbnail

Hot-melt extrusion can improve bioavailability: Avomeen

Outsourcing Pharma

With bioavailability challenges a frequent frustration for drug developers, one research outfit suggests a technique that could reduce the headaches.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study reveals oil type impacts CBD and THC bioavailability

BioPharma Reporter

New research reveals the bioavailability of both CBD and THC components of hemp, is higher when delivered in certain oil carriers, and describes how some CBD is converted into THC in the body.

article thumbnail

CellCentric Strengthens Leadership Team

Pharma Mirror

Both have stellar experience and track records in oncology research and development. CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications.

article thumbnail

Roquette opens pharmaceutical innovation facility in Pennsylvania, US

Pharmaceutical Technology

Situated at the hub of the country’s northeastern pharmaceutical corridor, the new facility is staffed by research, application and formulation specialists. It also aims to contribute to the pharmaceutical sector by facilitating cross-industry partnerships and research-based product development.

article thumbnail

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

In-Vivo 130
article thumbnail

Erasca receives fast track designation for glioblastoma therapy

Pharmaceutical Technology

The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. A team of three cancer researchers, Michael Jung, Timothy Cloughesy and David Nathanson, designed and developed ERAS-801.